You are here: Welcome » pharmaceutical_companies » Reliance Life Sciences

Menu

Rounding The Earth

Operation Uplift

Project List

Table of Contents

Reliance Life Sciences

Reliance Life Sciences is an Indian biopharmaceutical company based in Mumbai, India.

History

COVID-19

Reliance is developing a “second-generation” two antigen subunit protein COVID-19 vaccine called RelCoVax.1) On September 21, 2021, Dr. Robert Malone pitched RelCoVax to an online audience at the Vaccines Summit-2021.2) 3)

1)
Phatarphekar, A., Vidyadhar Reddy, G. E. C., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., Ramnath, R. L., Pratap Reddy, K., Rao, P., Harinarayana Rao, S., & Ramana, V. (2022). RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. Vaccine, 40(32), 4522–4530. https://doi.org/10.1016/j.vaccine.2022.06.026
2)
Housatonic. (2023, February 6). (Sep 21 2021) Robert malone: “RelCovax, 2ndGen multivalent SARS-CoV-2 vaccine candidate” (Summit). Rumble. https://web.archive.org/web/20230208073041/https://rumble.com/v28ntb2-sep-21-2021-robert-malone-relcovax-2ndgen-multivalent-sars-cov-2-vaccine-ca.html
3)
Speakers. Vaccines Summit-2021. Retrieved April 20, 2021, from https://web.archive.org/web/20210420005033/https://scientiameetings.com/conferences/vaccines/speakers
Back to top